

Referenties Ajovi®

1. <https://www.lumc.nl/org/hoofdijnderzoek/informatie/migraine/#:~:text=Migraine%20is%20een%20van%20de,%C3%A9%C3%A9n%20of%20twee%20aanvallen%20krijgen>
2. Samenvatting van de productkenmerken AJOVY: EU/1/19/1358 op <https://www.cbg-meb.nl>
3. Sacco S et al. J Headache Pain 2019; 20(1): 6.
4. Hepp Z et al. J Manag Care Pharm 2014; 20(1) 22–33
5. Dodick DW et al. JAMA 2018; 319(19):1999–2008.
6. Silberstein SD et al. N Engl J Med 2017; 377(22): 2113–2122
7. Ferrari MD et al. Lancet 2019; doi:10.1016/S0140-6736(19)31946-4

Referenties Arikayce® liposomal

1. Falkingham JO. Current Epidemiologic Trends of the Nontuberculous Mycobacteria (NTM). 2016; Curr Environ Health Rep. 3(2):161-7
2. Awuh JA and Flo TH. Molecular basis of mycobacterial survival in macrophages. 2017; Cell Mol Life Sci 74, 1625–1648
3. Qvist T et al. Chronic pulmonary disease with Mycobacterium abscessus complex is a biofilm infection. 2015; Eur Respir J, 46(6):1823-1826
4. Lipman M et al. Current and future management of non-tuberculous mycobacterial pulmonary disease (NTM-PD) in the UK. 2020; BMJ Open Respiratory Research, 7:e000591
5. Doyle OM et al. Identification of potentially undiagnosed patients with nontuberculous mycobacterial lung disease using machine learning applied to primary care data in the UK. 2020; Eur Respir J, 56(4):2000045
6. Ringshausen FC et al. Predictive modeling of nontuberculous mycobacterial pulmonary disease epidemiology using German health claims data. 2021; Int J Infect Dis, 11;104:398-406
7. Kotilainen H et al. Clinical findings in relation to mortality in nontuberculous
a. mycobacterial infections: Patients with Mycobacterium avium complex have better survival than patients with other mycobacteria. 2015; Eur J Clin Microbiol Infect Dis, 34(9):1909-1918 2015
8. Wagner D et al. Annual prevalence and treatment estimates of nontuberculous mycobacterial pulmonary disease in Europe: A NTM-NET collaborative study. 2014; Eur Respir J, 44(Suppl 58):P1067
9. Metha M and Marras TK. Impaired health-related quality of life in pulmonary nontuberculous mycobacterial disease. 2011; Respir Med, 105(11):1718-1725
10. Diel R et al. High mortality in patients with Mycobacterium avium complex lung disease: a systematic review. 2018; BMC Infect Dis, 18(1):1-10 2016
11. Park HY et al. Lung function decline according to clinical course in nontuberculous mycobacterial lung disease. 2016; Chest, 150(6):1222-1232 2016
12. Park HY et al. Natural course of the nodular bronchiectatic form of Mycobacterium avium complex lung disease: Long-term radiologic change without treatment. 2017; PLoS One, 12(10):1-11. 2019
13. Goring SM et al. The cost of Mycobacterium avium complex lung disease in Canada, France, Germany, and the United Kingdom: a nationally representative observational study 2018; BMC Health Services Research, 18:700
14. Dayley C et al. Treatment of nontuberculous Mycobacterial Pulmonary Disease: an official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. 2020; Eur Respir J, 56:2000535
15. Expertise centrum <https://www.radboudumc.nl/expertisecentra/expertisecentra-zeldzame-aandoeningen/tuberculose-en-nontuberculeuze-mycobacteriele-infectieziekten>
16. Zhang J et al. Amikacin liposome inhalation suspension (ALIS) penetrates non-tuberculous mycobacterial biofilms and enhances amikacin uptake into macrophages. 2018; Front Microbiol, 9:1-12 2018
17. Griffith DE et al. Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by Mycobacterium avium complex (CONVERT): A prospective, open-label, randomized study. 2018; Am J Respir Crit Care Med, 198(12):1559-1569 2018

Referenties Comirnaty®

1. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW Jr, Hammitt LL, TÜreci Ö, Nell H, Schaefer A, Ünal S, Tresnan DB, Mather S, Dormitzer PR, Sahin U, Jansen KU, Gruber WC; C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10. PMID: 33301246; PMCID: PMC7745181
2. Samenvatting van productkenmerken en EPAR te raadplegen via <https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty>

3. Noa Dagan, M.D., Noam Barda, M.D., Eldad Kepten, Ph.D., Oren Miron, M.A., Shay Perchik, M.A., Mark A. Katz, M.D., Miguel A. Hernán, M.D., Marc Lipsitch, D.Phil., Ben Reis, Ph.D., and Ran D. Balicer, M.D. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting | NEJM February 24, 2021 DOI: 10.1056/NEJMoa2101765

Referenties COVID-19 vaccine Moderna

1. <https://www.undp.org/content/undp/en/home/coronavirus/socio-economic-impact-of-covid-19.html>
2. Johns Hopkins University & Medicine, Coronavirus Resource Center - Global Covid Death confirmed and probable where reported <https://coronavirus.jhu.edu/map.html>
3. <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/mrna.html>
4. <https://www.nejm.org/doi/full/10.1056/NEJMoa2035389>
5. <https://www.ema.europa.eu/en/news/ema-recommends-covid-19-vaccine-moderna-authorisation-eu>

Referenties Givlaari®

1. Te Velde, K. Et al. Een familie-onderzoek bij de eerste Nederlandse patiënten met porfyrie NTVG; 1989;13,5:1:2547-2551. Te Velde, K. Nederlandse families met acute porfyrie; 2010
2. Neeleman, RA, et al. Diagnostic and therapeutic strategies for porphyrias; Neth. J. Med. 2020;78,4:149-160
3. Balwani, M, et al. Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria; N Engl J Med 2020;382:2289-301
4. AS1-NLD-00037 Version: April 2020

Referenties Jyseleca®

1. SmPC Jyseleca®. September 2020.
2. <https://www.volksgezondheidszorg.info/onderwerp/reumatoïde-artritis-ra-bezocht-op-22-februari-2021>
3. Prince FH, et al. Arthritis Res Ther 2012; 14:R68
4. Hamann PDH, et al. Rheumatology (Oxford) 2019; pii: kez188
5. Yu C, et al. Clin Rheumatol 2019; 38:727-738

Referenties Kaftrio®

1. European Cystic Fibrosis Society. 2017 ECFS Patient Registry Annual Data Report. Karup, Denmark: European Cystic Fibrosis Society; 2019
2. Heijerman H, De Jonge H. Expressie van het cystische-fibroze-gen in de longen. Ned Tijdschr Geneesk 2004;148:816-819
3. Van de Belt E, Kraan J, Bouman K, et al. Klinische manifestaties cystische fibrose bij volwassen patiënten. Ned Tijdschr Geneesk 2009;153:B155
4. Rommens JM, Iannuzzi MC, Kerem B, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 1989;245:1059-1065
5. Nederlandse Cystic Fibrosis Registratie. Rapportage van Het Jaar 2019. <https://ncfs.nl/wp-content/uploads/2021/01/CF-Registratie-2019-rapport-NL.pdf>. Geraadpleegd januari 2021
6. Heijerman HGM, McKone EF, Downey DG, et al. Efficacy and safety of the elxacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet 2019;394:1940-1948
7. Middleton PG, Mall MA, Drevinek P, et al. Elxacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med 2019;381:1809-1819

Referenties Libtayo®

1. SmPC Libtayo. Website CBG, Geneesmiddeleninformatiebank. 2021. Bezocht op 9 feb 2021. Beschikbaar op: <https://www.geneesmiddeleninformatiebank.nl/nl/>
2. Integraal Kanker Centrum Nederland. Rapport Huidkanker in Nederland. 2019. Bezocht op 9 feb 2021. Beschikbaar op: https://www.iknl.nl/docs/default-source/PDF_Docs/iknl_huidkanker-in-nl_rapport_nkr.pdf?sfvrsn=2
3. European Medicines Agency. EPAR - Public Assessment Report Libtayo. 2019. Bezocht op 16 feb 2021. Beschikbaar op: https://www.ema.europa.eu/en/documents/assessment-report/libtayo-epar-public-assessment-report_en.pdf
4. Migden M, Khushalani N, Chang A, et al. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. The Lancet Oncology. 2020; 21(2)
5. Rischin D, Migden M, Lim A, et al. Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing. Journal for ImmunoTherapy of Cancer. 2020;(8:e000775)
6. NVMO. Website Nederlandse Vereniging voor Medische Oncologie. 2021. Bezocht op 17 feb 2021. Beschikbaar op: <https://www.nvmo.org/2021/01/drug-access-protocol-gestart/>

Referenties Luxturna®

1. SmPC Voretigene Neparvovec (Luxturna) 2020. Beschikbaar op <https://www.novartis.nl/medicijnen/luxturna>
2. Chung DC, Bertelsen M, Lorenz B, et al. The Natural History of Inherited Retinal Dystrophy Due to Biallelic Mutations in the RPE65 Gene. *Am J Ophthalmol*. 2019;199:58-70. doi:10.1016/j.ajo.2018.09.024
3. Lloyd A, Piglowska N, Ciulla T, et al. Estimation of impact of RPE65-mediated inherited retinal disease on quality of life and the potential benefits of gene therapy. *Br J Ophthalmol*. Published online January 18, 2019;bjophthalmol-2018-313089. doi:10.1136/bjophthalmol-2018-313089
4. www.horizonscangeneesmiddelen.nl/geneesmiddelen/voretigene-neparvovec-neurologische-aandoeningen-ooogaandoeningen/versie7 (8 december 2020).
5. Russell S, Bennett J, Wellman JA, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. *Lancet* (London, England). 2017;390(10097):849-860. doi:10.1016/S0140-6736(17)31868-8
6. European Medicines Agency (EMA). EPAR Voretigene Neparvovec (Luxturna). 2018
7. Maguire AM, Russell S, Wellman JA, et al. Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation-Associated Inherited Retinal Dystrophy. *Ophthalmology*. 2019;126(9):1273-1285. doi:10.1016/j.ophtha.2019.06.017
8. Leroy BP. Webcast: Retinal Gene Therapy and the Patient Experience. EURETINA 2019. <https://eyetube.net/collections/retinal-gene-therapy/retinal-gene-therapy-and-the-patient-experience/> (password: novartis2019)

Referenties Ondexxya®

1. SmPC Ondexxya®, vanaf juni 2019
2. <https://www.ema.europa.eu/en/medicines/human/EPAR/ondexxya/authorisation-details-section>
3. Kuramatsu JB, Sembill JA, Huttner HB. *Critical Care*. 2019 Jun 6;23:206
4. Camm AJ et al. *Europace*. 2010 Oct;12(10):1360-1420
5. Piccini JP et al. ; *Eur Heart J*. 2014; 35 (28): 1873-1880
6. Hero C et al. *Eur Heart J*. 2015; 36: 1264-1272
7. Hankey GJ et al. *Stroke*. 2014;45:1304-1312
8. Lu G et al. *Nature Med*. 2013;19(4):446-451
9. Siegal DM et al. *N Engl J Med*. 2015;373:2413-2424. 7
10. Connolly S et al. *N Engl J Med*. 2019 Apr 4;380(14):1326-1335

Referenties Rybelsus®

1. NHG-standaard Diabetes mellitus type 2, www.nhg.org
2. Diabetes mellitus type 2 in de tweede lijn, Nederlandse Internisten Vereniging; 2018, <https://richtlijndatabase.nl>
3. Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. *Diabetologia*. 2009;52(10):2046-55
4. Giorgino F, Benroubi M, Sun JH, Zimmermann AG, Pechter V. Efficacy and safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2). *Diabetes Care*. 2015;38(12):2241-9
5. Aroda VR, Bain SC, Cariou B, Piletic M, Rose L, Axelsen M, et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naïve patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. *The Lancet Diabetes & Endocrinology*. 2017;5(5):355-66
6. Zorginstituut Nederland. Bijlage 2 voorwaarden GLP-1 receptoragonisten toegevoegd aan orale medicatie, <https://www.farmacotherapeutischkompas.nl/algemeen/regeling-zorgverzekering#bijlage-2-bij-de-regeling-zorgverzekering>
7. Khunti S, Khunti K, Seidu S. Therapeutic inertia in type 2 diabetes: prevalence, causes, consequences and methods to overcome inertia. *Therapeutic Advances in Endocrinology and Metabolism*. 2019;10:2042018819844694
8. Buckley ST, Bækdal TA, Vegge A, Maarbjerg SJ, Pyke C, Ahnfeldt-Rønne J, et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. *Science Translational Medicine*. 2018;10(467)
9. Pratley R, Amod A, Hoff ST, Kadowki T, Lingvay I, Nauck M, et al. Oral semaglutide versus subcutaneous liraglutide ad placebo in type 2

- diabetes (PIONEER 3): a randomised, double-blind, phase 3a trial. *Lancet* (London, England). 2019;394(10192):39-50
10. Thethi TK, Pratley R, Meier JJ. Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme. *Diabetes, Obesity & Metabolism*. 2020;22(8):1263-77
NL21RYB00016

Referenties Veklury®

1. Novel Coronavirus (2019-nCoV) SITUATION REPORT – 1 21 JANUARY 2020. Available from: <https://www.who.int/docs/default-source/coronavirus/situation-reports/20200121-sitrep-1-2019-ncov.pdf>. Accessed: February 2021
2. Sheahan TP et al. *Sci Trans Med*. 2017
3. Williamson B, et al. *Nature*. 2020;585:273-276. <https://doi.org/10.1038/s41586-020-2423-5>
4. Grein et al. *NEJM* June 2020
5. EPAR Veklury. Available from: <https://www.ema.europa.eu/en/medicines/human/EPAR/veklury>. Accessed: February 2021
6. Summary of product characteristics Veklury, latest version. Available from: https://www.geneesmiddeleninformatiebank.nl/ords/f?p=111:3::SEARCH:NO::PO_DOMAIN,PO_LANG,P3_RVG1:H,NL,126777. Accessed: February 2021
7. Tchesnokov EP, et al. *J Biol Chem*. 2020. <https://dx.doi.org/10.1074/jbc.AC120.015720>
8. Beigel JH et al. *NEJM* October 2020
9. About Veklury. Available from: <https://www.gilead.com/purpose/advancing-global-health/covid-19/about-veklury>. Accessed February 2021
10. Gilead. Development of remdesivir. Available from: <https://www.gilead.com/-/media/files/pdfs/medicines/covid-19/veklury/veklury-remdesivir-development-background.pdf?la=en&hash=3B814B9901483A3941ACF9D066056366>. Accessed February 2021
11. World Health Organisation. WHO Timeline – COVID-19. Available from: <https://www.who.int/news-room/detail/27-04-2020-who-timeline---covid-19>. Accessed November 2020.
12. Working to supply Veklury for COVID-19. Available from: <https://www.gilead.com/purpose/advancing-global-health/covid-19/working-to-supply-veklury-for-covid-19>. Accessed February 2021
13. Goldman JD, Lye DCB, Hui DS, Marks KM, Bruno R, Montejano R, et al. Remdesivir for 5 or 10 days in patients with severe Covid-19. *N Engl J Med*. doi: 10.1056/NEJMoa2015301. pmid:32459919
14. Spinner CD, Gottlieb RL, Criner GJ, Arribas Lopez JR, Cattelan AM, Soriano Viladomiu A et al. Effects of Remdesivir vs. Standard Care on Clinical Status at 11-Day in patients with Moderate COVID-19: A Randomized Clinical Trial. *JAMA*. Published online August 21, 2020. doi: 10.1001/jama.2020.16349. pmid:32821939
15. Gordon CJ, et al. *J Biol Chem*. 2020; 295: 6785-6797
16. An update on COVID-19 from Gilead's chairman & CEO. Available from: <https://stories.gilead.com/articles/an-update-on-covid-19-from-our-chairman-and-ceo>. Accessed February 2021

Referenties Vitrakvi®

1. EMA approval VITRAKVI (larotrectinib). 2019. <https://www.ema.europa.eu/en/medicines/human/EPAR/vitrakvi>
2. SmPC VITRAKVI® (larotrectinib), 08/2020.
3. Hong DS, et al. *Lancet Oncol* 2020;21(4):531-540
4. Drilon A, et al. *J Clin Oncol* 2019;37(suppl): Abstract 2006. Oral presentation at ASCO 2019
5. Italiano A, et al. *Cancers* 2020, 12, 3246
6. Kummar S, et al. *J Clin Oncol* 2020; 38(suppl): Abstract 3614. Poster presentation at ASCO 2020
7. Marieke ten Katen en Rob Ramaker, Elsevier weekblad, 2 november 2019: 68-71
8. Laetsch TW, et al. *J Clin Oncol* 2017; 35: 10510

Referenties Yescarta®

1. Concept Richtlijn Diffuus grootcellig B-cel non-Hodgkin lymfom (DLBCL), 2019
2. Crump M, Neelapu SS, et al. *Blood*. 2017 Oct 19;130(16):1800-1808
3. SmPC Yescarta
4. Locke et al. *Lancet Oncol*. 2019;20(1):31-42
5. I. Hegger, R.A.A. Vonk, M.Weda, Toekomstverwachtingen over ATMPs, RIVM Briefrapport 2017-0168
6. EMA. Yescarta EPAR Annex Summary of Product Characteristics SmPC (2018)